Dec 7 (Reuters) - Gilead Sciences Inc GILD.O :
* Health Canada issues notice of compliance for gilead's single tablet regimen
Genvoya(TM) (elvitegravir, cobicistat, emtricitabine and tenofovir
alafenamide) for treatment of hiv-1 infection
* Says marketing authorization is supported by a phase 3 study (study 109)
among virologically-suppressed adult patients
* Source text for Eikon
* Further company coverage GILD.O